A patient with KRAS mutant metastatic colorectal cancer has been successfully treated with an autologous T cell receptor therapy, suggesting there may be a path forward for tackling difficult solid tumours, according to Kite Pharma Inc. ---Subscribe to MedNous to access this article--- Clinical Research Regenerative Medicine Company News
